Neogenomics (NEO) Operating Leases (2019 - 2026)

Neogenomics (NEO) has 8 years of Operating Leases data on file, last reported at $64.7 million in Q2 2026.

• Quarterly Operating Leases fell 2.92% year-over-year to $64.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $64.7 million (down 2.92% YoY) and the FY2025 annual result came in at $62.8 million, up 3.26% from the prior year.
• Operating Leases climbed to $64.7 million in Q2 2026, from $61.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $73.4 million in Q1 2022 to a low of $59.9 million in Q1 2025.
• A 5-year average of $65.5 million and a median of $64.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 42.46% — and 2023, when it dropped 12.01%.
• Tracing NEO's Operating Leases over 5 years: stood at $69.0 million in 2022, then retreated by 1.57% to $67.9 million in 2023, then decreased by 10.36% to $60.8 million in 2024, then increased by 3.26% to $62.8 million in 2025, then rose by 2.94% to $64.7 million in 2026.
• The last three Operating Leases figures came in at $64.7 million (Q2 2026), $61.5 million (Q1 2026), and $62.8 million (Q4 2025), per Business Quant data.